
Psychemedics Corporation PMD
Quarterly report 2024-Q3
added 11-12-2024
Psychemedics Corporation Total Liabilities 2011-2026 | PMD
Annual Total Liabilities Psychemedics Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.65 M | 7.96 M | 9.31 M | 11.5 M | 10.7 M | 6.23 M | 7.89 M | 9.42 M | 10.7 M | 11.2 M | 4.27 M | 2.9 M | 2.77 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 11.5 M | 2.77 M | 7.73 M |
Quarterly Total Liabilities Psychemedics Corporation
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.39 M | 4.37 M | 4.87 M | 5.65 M | 6.68 M | 7.26 M | 7.74 M | 7.96 M | 8.76 M | 8.51 M | 8.51 M | 9.31 M | 9.61 M | 11.5 M | 11.6 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 6.23 M | 6.23 M | 6.23 M | 6.23 M | 7.89 M | 7.89 M | 7.89 M | 7.89 M | 9.42 M | 9.42 M | 9.42 M | 9.42 M | 10.4 M | 10.7 M | 10.7 M | 10.7 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M | 4.27 M | 4.27 M | 4.27 M | 4.27 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.77 M | 2.77 M | 2.77 M | 2.77 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 11.6 M | 2.77 M | 7.76 M |
Total Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
58.6 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
1.62 B | - | -17.87 % | $ 25.9 M | ||
|
Brainsway Ltd.
BWAY
|
14.4 M | $ 13.65 | -0.44 % | $ 99.4 M | ||
|
Aspira Women's Health
AWH
|
10.6 M | - | -6.19 % | $ 10.5 M | ||
|
Bioventus
BVS
|
455 M | $ 8.87 | 2.9 % | $ 591 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
21.6 M | - | - | $ 562 M | ||
|
Charles River Laboratories International
CRL
|
3.92 B | $ 151.97 | -2.34 % | $ 7.53 B | ||
|
Castle Biosciences
CSTL
|
75.4 M | $ 25.83 | 1.06 % | $ 717 M | ||
|
CareDx, Inc
CDNA
|
110 M | $ 17.32 | 1.82 % | $ 923 M | ||
|
DexCom
DXCM
|
3.59 B | $ 66.34 | 3.27 % | $ 25.9 B | ||
|
Accelerate Diagnostics
AXDX
|
87.3 M | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
3.46 B | $ 103.85 | 0.27 % | $ 19.6 B | ||
|
Global Cord Blood Corporation
CO
|
3.65 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
186 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
4.37 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
427 M | - | 0.12 % | $ 80.1 M | ||
|
Fulgent Genetics
FLGT
|
90.8 M | $ 14.95 | 1.22 % | $ 452 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
2.7 B | - | - | $ 10.7 B | ||
|
Biodesix
BDSX
|
76.4 M | $ 17.29 | -3.3 % | $ 2.24 B | ||
|
Guardant Health
GH
|
2.11 B | $ 87.18 | 1.98 % | $ 10.9 B | ||
|
Anixa Biosciences
ANIX
|
2.13 M | $ 2.84 | 0.35 % | $ 92.2 K | ||
|
Danaher Corporation
DHR
|
31.8 B | $ 191.39 | 2.17 % | $ 136 B | ||
|
Biocept
BIOC
|
22 M | - | -13.05 % | $ 7.29 M | ||
|
Heska Corporation
HSKA
|
164 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
12.4 M | - | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
7.35 B | $ 97.61 | -0.73 % | $ 8.05 B | ||
|
IQVIA Holdings
IQV
|
23.3 B | $ 164.89 | 0.1 % | $ 28.3 B | ||
|
Illumina
ILMN
|
2.7 B | $ 119.28 | 0.29 % | $ 19 B | ||
|
Quest Diagnostics Incorporated
DGX
|
7.16 B | $ 198.94 | -0.38 % | $ 22.1 B | ||
|
QIAGEN N.V.
QGEN
|
3.11 B | - | - | $ 10.6 B | ||
|
Agilent Technologies
A
|
5.32 B | $ 111.83 | 0.28 % | $ 34 B | ||
|
BioNano Genomics
BNGO
|
41.3 M | $ 1.11 | - | $ 1.41 M | ||
|
DarioHealth Corp.
DRIO
|
7.26 M | $ 8.42 | -6.44 % | $ 239 M | ||
|
Lantheus Holdings
LNTH
|
1.14 B | $ 78.5 | -1.25 % | $ 5.3 B | ||
|
Chembio Diagnostics
CEMI
|
44.8 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
1.83 M | - | - | $ 9.42 M | ||
|
Co-Diagnostics
CODX
|
9.31 M | $ 4.4 | 101.83 % | $ 129 M | ||
|
Medpace Holdings
MEDP
|
1.52 B | $ 453.64 | 0.72 % | $ 13.1 B | ||
|
Motus GI Holdings
MOTS
|
4.54 M | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
3.74 B | $ 1 198.71 | 2.13 % | $ 24.7 B | ||
|
Celcuity
CELC
|
130 M | $ 114.9 | 0.6 % | $ 4.53 B | ||
|
DermTech
DMTK
|
64.8 M | - | -11.32 % | $ 2.94 M | ||
|
Neogen Corporation
NEOG
|
1.37 B | $ 9.11 | 0.22 % | $ 1.98 B | ||
|
National Research Corporation
NRC
|
121 M | $ 17.4 | 5.33 % | $ 389 M | ||
|
NeoGenomics
NEO
|
523 M | $ 8.24 | 4.57 % | $ 1.06 B | ||
|
Invitae Corporation
NVTA
|
1.85 B | - | - | $ 21.2 M | ||
|
Enzo Biochem
ENZ
|
29.7 M | - | -8.98 % | $ 14.8 K | ||
|
Natera
NTRA
|
689 M | $ 197.68 | 5.23 % | $ 19.5 B | ||
|
OPKO Health
OPK
|
835 M | $ 1.19 | - | $ 826 M | ||
|
Pacific Biosciences of California
PACB
|
779 M | $ 1.36 | 2.26 % | $ 408 M |